by Wiley Credit: CC0 Public Domain Numerous studies have shown that drugs called immune checkpoint inhibitors can boost the immune system’s response against various cancers. Now a phase II clinical trial has demonstrated that patients with a serious form of skin cancer called advanced cutaneous squamous cell carcinoma can benefit from the immune checkpoint inhibitor...
OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER COLUMBUS, Ohio – A cancer immunotherapy drug currently approved by the U.S. Food and Drug Administration (FDA) to treat several forms of cancer is also effective for treating aggressive forms of endometrial (uterine) cancer, according to results from an international phase II clinical trial led by researchers at The Ohio...
by Dana-Farber Cancer Institute Credit: Unsplash/CC0 Public Domain Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of phase 3 clinical trial of adjuvant immunotherapy in this patient population. Patients who were treated for nearly a year with pembrolizumab experienced...
by Dennis Thompson An immunotherapy drug is the first to significantly reduce the risk of cancer recurrence or death in people with early-stage lung cancer, researchers report. Atezolizumab reduced by 34% the risk of disease recurrence or death in a certain group of people with stage II to IIIA non-small cell lung cancer —those whose tumors carry a protein...
by University of Calgary Researchers with the Snyder Institute for Chronic Diseases at the Cumming School of Medicine (CSM) have discovered which gut bacteria help our immune system battle cancerous tumors and how they do it. The discovery may provide a new understanding of why immunotherapy, a treatment for cancer that helps amplify the body’s...
by Anne Doerr, Yale University Lung cancer spreads to the brain in about one-quarter of patients with an advanced form of the disease. To date, radiation has been the only treatment option, but it comes with toxic side effects. Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab in...
An existing immunotherapy drug called pembrolizumab appears to be effective in the treatment of malignant pleural mesothelioma, a rare and aggressive lung cancer that is primarily caused by exposure to asbestos. Writing in The Lancet Oncology, researchers describe the first study to show a positive result from using the antibody drug against this rare cancer. Researchers...
